NCT07415031phase 2recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Mirati Therapeutics Inc.

ClinicalTrials.gov

170

Enrollment · estimated

Countries · 100 sites

2028-02

Primary completion

22 days ago

Record updated

Commercial relevance

No explicit biomarker / molecular-testing language identified in the public record.

Biomarker requirement language

Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
42/100
Opportunity
New phase 2 trial NCT07415031 posted by Mirati Therapeutics Inc.: "A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies".
ClinicalTrials.gov record updated 21 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

* Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
* Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.

Exclusion Criteria:

* Participant is not eligible for study treatment per the parent study eligibility criteria.
* Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study.
* Participants not receiving clinical benefit from parent study drug as assessed by the investigator.

Other protocol defined inclusion/exclusion criteria applies.